Cytisinicline for Vaping Cessation in Adults Using Nicotine E-Cigarettes: The ORCA-V1 Randomized Clinical Trial.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

The prevalence of e-cigarette use among US adults, especially young adults, is rising.

Many would like to quit vaping nicotine but are unable to do so.

Who Took Part

The abstract describes 160 adults taking part.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Therapeutic nicotine (patch, non-peptide) group a baseline to be compared against.

It was conducted from July 2022 to February 2023 across 5 US clinical trial sites.

What Was Measured

Topics PubMed links to this paper include Azocines, Electronic Nicotine Delivery Systems, Nicotinic Agonists, Smoking Cessation, Tobacco Use Disorder and Vaping.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 160 adults.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (JAMA internal medicine), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.